Iressa Home image1

IRESSA (gefitinib) as a first-line treatment for EGFR mutation-positive advanced NSCLC

IRESSA is a highly convenient, once-daily oral tablet that offers superior progression-free survival, better tolerability and quality of life compared with doublet chemotherapy (carboplatin/paclitaxel) as first-line treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC).

Read more

Over 10 years of real-world experience

IRESSA is a standard of care treatment across multiple countries in adults with EGFR mutation-positive advanced NSCLC, due to its consistent efficacy and differentiated safety profile as demonstrated by four pivotal trials

Read more

Identifying EGFR mutation-positive patients

EGFR is a protein found in abnormally high levels on the surface of many types of cancer cells, particularly NSCLC cells. A patient‘s EGFR mutation status (positive or negative) can be confirmed via a diagnostic test using a sample of tumour tissue or plasma (for circulating tumour DNA testing).

Read more

This content is not currently available for your device.



  1. Cohen MH et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa®) tablets. Oncologist 2003;8:303-306.
  2. AstraZeneca data on file.
  3. Mok TS et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
  4. Mitsudomi T et al; the West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
  5. Maemondo M et al; the North-East Japan Study Group. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
  6. Douillard J-Y et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 2014;110:55-62.